GlobeNewsWire
10 Sept 2026, 02:32 UTC · 1d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
The FDA considers the analyses of Capricor's lead product candidate, Deramiocel, to be post-hoc and exploratory due to unapproved changes in the statistical analysis plan. — Regulatory rejection of primary efficacy data usually leads to severe devaluation of a biotech company's lead asset.
-0.90The FDA stated that the benefit-risk profile for deramiocel appeared unfavorable given the lack of evidence supporting its effectiveness. — Direct negative feedback from the FDA regarding a drug's benefit-risk profile significantly lowers the probability of BLA approval.
-0.80Capricor Therapeutics is facing a securities class action lawsuit alleging failure to disclose material information between December 2025 and July 2026. — Litigation creates financial liability and management distraction, though it is secondary to the underlying clinical failure.
-0.40Which stocks this story touches
Continue reading
5 related stories
Search tags
The company is facing a securities class action lawsuit and an unfavorable FDA review of its lead product candidate, resulting in a 64% stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
1h ago
